Quest Diagnostics Incorporated (DGX): Price and Financial Metrics
Quest Diagnostics Incorporated (DGX)
Today's Latest Price: $120.83 USD
Updated Oct 19 6:30pm
Add DGX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
DGX Stock Summary
- DGX has a higher market value than 88.8% of US stocks; more precisely, its current market capitalization is $16,143,176,246.
- With a one year PEG ratio of 564.28, Quest Diagnostics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.75% of US stocks.
- Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 98.31% of US stocks have a lower such ratio.
- Stocks with similar financial metrics, market capitalization, and price volatility to Quest Diagnostics Inc are HUBB, MKC, WRK, MIDD, and IEX.
- DGX's SEC filings can be seen here. And to visit Quest Diagnostics Inc's official web site, go to www.questdiagnostics.com.
DGX Stock Price Chart Interactive Chart >
DGX Price/Volume Stats
| Current price | $120.83 | 52-week high | $131.81 |
| Prev. close | $120.20 | 52-week low | $73.02 |
| Day low | $120.31 | Volume | 1,075,843 |
| Day high | $121.77 | Avg. volume | 1,543,107 |
| 50-day MA | $115.00 | Dividend yield | 1.86% |
| 200-day MA | $109.85 | Market Cap | 16.23B |
Quest Diagnostics Incorporated (DGX) Company Bio
Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.
DGX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $120.83 | $86.61 | -28% |
Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DGX, they are:
- As a business, DGX is generating more cash flow than 76.33% of positive cash flow stocks in the Healthcare.
- Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 14.75% of tickers in our DCF set.
- DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 14.75% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -29% |
| 1% | -29% |
| 2% | -28% |
| 3% | -27% |
| 4% | -27% |
| 5% | -26% |
STE, PAHC, BDX, CNC, and EBS can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...